This data set includes data from the PfSPZ Vaccine trial data analyzed in "Can incorporating genotyping data into efficacy estimators improve efficiency of early phase malaria vaccine trials?", by Gail E. Potter, Viviane Callier, Biraj Shrestha, Sudhaunshu Joshi , Ankit Dwivedi, Joana C. Silva, Matthew B. Laurens, Dean A. Follmann, Gregory A. Deye The primary trial publication is: Sirima, Sodiomon B., Alphonse Ouédraogo, Alfred B. Tiono, Jean M. Kaboré, Edith C. Bougouma, Maurice S. Ouattara, Désiré Kargougou et al. "A randomized controlled trial showing safety and efficacy of a whole sporozoite vaccine against endemic malaria." Science Translational Medicine 14, no. 674 (2022): eabj3776. https://www.science.org/doi/full/10.1126/scitranslmed.abj3776 This Phase 2 trial included 80 adults randomized to PfSPZ Vaccine or placebo in Burkina Faso and followed for 168 days for malaria infection by thick blood smear microscopy. The data set includes treatment and infection indicators, time to first infection, and number of clones identified at the first infection.